Northwest Biotherapeutics | NWBO - Operating Expenses


Northwest Biotherapeutics reported $-108.65M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD 19.81M 293.94M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Celldex Therapeutics USD 87.27M 511.09M Dec/2025
Eisai JPY 199.9B 16.22B Dec/2025
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Merck USD 10.16B 558M Dec/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025